Back to top
more

Hims & Hers Health (HIMS)

(Delayed Data from NYSE)

$15.85 USD

15.85
18,131,491

-0.19 (-1.18%)

Updated Aug 8, 2024 04:00 PM ET

After-Market: $15.85 0.00 (0.00%) 5:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 43% (107 out of 250)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ethan Feller headshot

Eli Lilly: The Next $1 Trillion Market Cap Stock?

by Ethan Feller

Eli Lilly showcased the exceptional strength of its business during its quarterly earnings meeting on Thursday morning

Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 20% and 3.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?

by Debanjana Dey

Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Boston Scientific (BSX) Rides on Global Growth, Buyouts

by Zacks Equity Research

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Debanjana Dey headshot

Should You Buy Hims & Hers (HIMS) Stock Ahead of Q2 Earnings?

by Debanjana Dey

Continued solid uptake of Hims & Hers (HIMS) offerings and expanding subscriber base are likely to have driven its performance in the second quarter.

Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings

by Zacks Equity Research

Haemonetics' (HAE) first-quarter fiscal 2025 results are likely to reflect the benefits of hemostasis management growth.

Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can RadNet's (RDNT) Service Fee Revenues Help Lift Q2 Earnings?

by Zacks Equity Research

RadNet's (RDNT) Imaging Center segment is likely to have gained from the increased reimbursement from commercial and capitated payors and strong procedure volumes in the second quarter of 2024.

Can Hims & Hers Health (HIMS) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Here's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings

by Zacks Equity Research

Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery banking on strategic product launches in the second quarter.

Hims & Hers Health, Inc. (HIMS) Stock Moves -1.14%: What You Should Know

by Zacks Equity Research

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $22.51, indicating a -1.14% shift from the previous trading day.

Is Hims & Hers Health (HIMS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Hims & Hers Health, Inc. (HIMS) and TransMedics (TMDX) have performed compared to their sector so far this year.

Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings

by Zacks Equity Research

Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.

Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal

by Zacks Equity Research

Quest Diagnostics' (DGX) subsidiary, Haystack Oncology, partners on the use of its MRD technology.

How to Play Henry Schein (HSIC) Ahead of Q2 Earnings?

by Zacks Equity Research

Henry Schein (HSIC) is expected to deliver impressive sales in both its businesses in the second quarter of 2024, along with a steady pace of recovery from the cyber incident.

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

Here's How STERIS (STE) is Placed Ahead of Q1 Earnings

by Zacks Equity Research

STERIS' (STE) first-quarter fiscal 2025 results are likely to reflect the positives of the normalization of the Healthcare backlog, along with a core focus on pharma and MedTech.

Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Within Bio-Rad's (BIO) Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely impacted sales.

Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings

by Zacks Equity Research

IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.

Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release

by Zacks Equity Research

Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.

Globus Medical (GMED) Global Sales, Innovation Aid Growth

by Zacks Equity Research

In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.

Will Clear Aligner Sales Drive Align Technology's (ALGN) Q2 Earnings?

by Zacks Equity Research

Align Technology's (ALGN) second-quarter results are likely to reflect the strength in its Clear Aligner and Systems & Services businesses.

Hologic's (HOLX) Surgical Business Set to Propel Q3 Earnings

by Zacks Equity Research

Hologic (HOLX) is likely to have delivered impressive performances across the GYN Surgical and Breast Health businesses in the third quarter of fiscal 2024.

Will Patient Volumes Drive Universal Health's (UHS) Q2 Earnings?

by Zacks Equity Research

Universal Health's (UHS) Q2 performance is likely to gain from strong performances in its Acute Care Hospital Services and Behavioral Health Care Services segments.

Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D

by Zacks Equity Research

Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.